1-3 of 3
Emma Palfreyman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Venetoclax-Based Measurable Residual Disease Directed Therapy in Acute Myeloid Leukemia Is Associated with Emergent TP53 Microclones in Remission

Ing Soo Tiong, Satwica Yerneni, Tamia Nguyen, Adam Ivey, Natasha S. Anstee, Emma Palfreyman, Ashish Bajel, Emad Uddin Abro, Devendra Hiwase, Andrew H Wei, Piers Blombery
Journal: Blood
Blood (2024) 144 (Supplement 1): 51.
https://doi.org/10.1182/blood-2024-201145
Published: 2024
Journal Articles

A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia

Ing S Tiong, Devendra Hiwase, Emad Uddin Abro, Ashish Bajel, Emma Palfreyman, Sun Loo, Shaun Fleming, Chun Yew Fong, Tse-Chieh Teh, Adam Ivey, Andrew H Wei
Journal: Blood
Blood (2022) 140 (Supplement 1): 1453–1455.
https://doi.org/10.1182/blood-2022-163041
Published: 2022
Journal Articles

A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia

Ing S Tiong, Sun Loo, Emad Uddin Abro, Devendra Hiwase, Shaun Fleming, Ashish Bajel, Emma Palfreyman, Chun Yew Fong, Tse-Chieh Teh, Adam Ivey, Andrew H. Wei
Journal: Blood
Blood (2021) 138 (Supplement 1): 1261.
https://doi.org/10.1182/blood-2021-152583
Published: 2021